Clean Balance Sheet / Zero DebtZero reported debt and a material equity increase improve solvency and reduce near-term default risk. This durable capital-structure strength gives management flexibility to fund clinical programs or raise capital from a stronger balance-sheet position, lowering financing risk.

Revenue Rebound In 2025A rebound in revenue demonstrates early commercial or milestone traction after declines, signaling that underlying operations can generate growing top-line receipts. Over 2-6 months, continued growth off this base would support scaling and validate aspects of the business model.

Focused Therapeutic PipelineA clear strategic focus on a single mechanism (TRPV1 antagonist XEN-D0501) concentrates R&D resources and clarifies milestone pathways. Focused pipelines can yield higher probability of meaningful progress per dollar invested and make partnership or licensing discussions more straightforward.

Bears Say

Persistent Negative Free Cash FlowSustained negative operating and free cash flow indicates ongoing cash burn and dependence on external financing. Over months this constrains investment in trials, risks dilution on new raises, and forces management to prioritize programs, limiting long-term operational flexibility.

Widening Net LossesGrowing net losses erode equity and signal that operating costs outpace revenue growth. Persistently deep losses reduce runway, increase funding needs, and can delay commercialization or expansion plans, creating structural pressure on profitability and strategic options.

Small, Volatile Revenue And Limited ScaleA tiny, volatile revenue base and limited operating scale (1 employee reported) mean weak operating leverage and fragile commercial capability. The company remains highly dependent on R&D outcomes and external partners, increasing execution risk over the medium term.

PILA FAQ

What was PILA PHARMA AB’s price range in the past 12 months?

PILA PHARMA AB lowest stock price was kr1.02 and its highest was kr3.93 in the past 12 months.

What is PILA PHARMA AB’s market cap?

PILA PHARMA AB’s market cap is kr53.45M.

When is PILA PHARMA AB’s upcoming earnings report date?

PILA PHARMA AB’s upcoming earnings report date is Aug 20, 2026 which is in 160 days.

How were PILA PHARMA AB’s earnings last quarter?

PILA PHARMA AB released its earnings results on Feb 26, 2026. The company reported -kr0.369 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.369.

Is PILA PHARMA AB overvalued?

According to Wall Street analysts PILA PHARMA AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does PILA PHARMA AB pay dividends?

PILA PHARMA AB does not currently pay dividends.

What is PILA PHARMA AB’s EPS estimate?

PILA PHARMA AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does PILA PHARMA AB have?

PILA PHARMA AB has 45,682,120 shares outstanding.

What happened to PILA PHARMA AB’s price movement after its last earnings report?

PILA PHARMA AB reported an EPS of -kr0.369 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.83%.

Which hedge fund is a major shareholder of PILA PHARMA AB?

Currently, no hedge funds are holding shares in SE:PILA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PILA PHARMA AB

PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2a clinical trials for type 2 diabetes. PILA PHARMA AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.